Thanks for the opportunity. So, I have a few questions. If you can just tell what has been the impact of US tariffs in your international business as in if the tariffs were not there, then how would the performance have been, to what extent it would have improved?
Yes, but I was asking about the international market?
I have five, six, short questions. Sir, in the context of the new capex that is already on live and some of which is going to go live in a few months, how much dep reciation should we factor in per quarter going forward?
Yes. So, for example, this quarter, your depreciation was INR114 crores this quarter in the September quarter. So, on a monthly run rate, now if I take that 75 -- or on a quarterly run rate, are we saying that the depreciation is going to increase to INR125 crores, INR130 crores per quarter, something like that?
If I look at your financials 7-8 years ago, even 10 years ago, you used to operate at 20% margins and the profitability that you are touching now is the same profitability that you were at 10 years ago. So, while your revenue has grown over the last 10 years, but the net profit of the PAT is at the same level because of the lower margins of 13% to 14% in the last 4-5 years. So, is this the new normal, the 13% to 14% EBITDA margin, is it the new normal margin now?
Can you throw some light on the Bangladesh situation because my understanding is that you do a lot of exports to Bangladesh. So, how was the demand impacted and for the brief time that the demand was impacted, did you get replacement demand from India yarn buyers? Can you throw some light on that?
Hello, sir. I have two questions. What will be the interest cost trajectory over the next 4-8 quarters? Will the interest cost remain elevated such that the major part of the growth in revenue and EBITDA will be eaten up by the interest and even the employee costs? And when will the PAT growth start becoming visible?
That will be from as soon as the next quarter or 3-4 quarters down the line?
I have 2 questions. So the first question is like, what could be the impact of the biopharma on NATCO Pharma business in your assessment?
Okay. The second question is, how is your agro business doing? And what is the outlook for FY '26 specifically on the agro side?